Takeaways from the most recent news in the technology and policies shaping healthcare.
Virtual care and remote monitoring: adoption, reimbursement, and how digital-first delivery is settling into everyday practice.
KFF Health News journalists broke down telehealth's uncertain federal future, ACA enrollment, and HHS's Covid injury list across a round of media appearances.
Why it matters: Telehealth reimbursement and access still depend on short-term federal extensions, leaving virtual-care operators unable to plan long term.
Becker's Hospital Review named 272 telehealth companies to know for 2026, reflecting how virtual care became permanent, crowded, and increasingly specialized.
Why it matters: The scale of the list shows telehealth is now core healthcare infrastructure, raising the bar for vendors to prove value beyond access.
The NBA players union named Teladoc Health its preferred virtual care provider in a multiyear deal covering active and retired players and their families.
Why it matters: A high-profile institutional endorsement gives Teladoc a marketing win as it fights to stabilize growth in a crowded telehealth market.
DiMe launched an initiative to help payers and virtual care providers navigate the contract implementation problems that commonly stall virtual-first care programs.
Why it matters: Contract friction, not technology, is often what stalls virtual care programs, and standardizing implementation could help the model scale.
Telehealth and digital tools are expanding access to pediatric behavioral healthcare, but integration into primary care and proven outcomes remain the key tests.
Why it matters: A severe shortage of pediatric mental health providers means technology may be the only scalable way to reach kids in crisis, if it actually works.
Vida Health partnered with Instacart to provide members grocery stipends for healthy foods as part of its cardiometabolic care programs.
Why it matters: Linking clinical care to actual groceries tests whether food-as-medicine can improve chronic disease outcomes and cut costs at scale.
GLP-1 drugs are a $70 billion market, but weak clinical follow-up pushes patients to TikTok for dosing and side-effect advice.
Why it matters: Poor support between prescription and use threatens patient safety and adherence, and creates a major opening for digital health.